Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
$12.40
-6.6%
$11.64
$4.81
$27.50
$414.46MN/A259,244 shs199,130 shs
MEM
Matthews Emerging Markets Equity Active ETF
$32.55
+0.1%
$31.45
$26.07
$36.15
$39.71M0.849,902 shs2,303 shs
Permian Basin Royalty Trust stock logo
PBT
Permian Basin Royalty Trust
$12.76
$11.46
$8.01
$14.26
$597.06M0.58142,449 shs89,485 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
-6.63%-0.60%+8.30%+67.34%+1,239,999,900.00%
MEM
Matthews Emerging Markets Equity Active ETF
+0.09%-0.61%+1.97%+16.08%+3.17%
Permian Basin Royalty Trust stock logo
PBT
Permian Basin Royalty Trust
-0.47%-1.28%+11.25%+32.85%+8.23%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
2.5843 of 5 stars
3.50.00.00.02.71.70.6
MEM
Matthews Emerging Markets Equity Active ETF
N/AN/AN/AN/AN/AN/AN/AN/A
Permian Basin Royalty Trust stock logo
PBT
Permian Basin Royalty Trust
2.1157 of 5 stars
0.05.01.70.03.50.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
3.00
Buy$37.50202.42% Upside
MEM
Matthews Emerging Markets Equity Active ETF
2.79
Moderate Buy$32.55N/A
Permian Basin Royalty Trust stock logo
PBT
Permian Basin Royalty Trust
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/AN/AN/AN/AN/A
MEM
Matthews Emerging Markets Equity Active ETF
N/AN/AN/AN/AN/AN/A
Permian Basin Royalty Trust stock logo
PBT
Permian Basin Royalty Trust
$26.96M22.06$0.55 per share23.40N/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/A0.00N/AN/AN/AN/AN/AN/A
MEM
Matthews Emerging Markets Equity Active ETF
N/AN/A15.50N/AN/AN/AN/AN/A
Permian Basin Royalty Trust stock logo
PBT
Permian Basin Royalty Trust
$25.42M$0.4926.04N/A93.60%12,661.40%593.31%8/6/2025 (Estimated)

Latest REDX, IXI, MEM, PBT, and MBX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Permian Basin Royalty Trust stock logo
PBT
Permian Basin Royalty Trust
N/A$0.06N/A$0.06N/A$3.07 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/AN/AN/AN/A
MEM
Matthews Emerging Markets Equity Active ETF
$2.266.94%N/AN/AN/A
Permian Basin Royalty Trust stock logo
PBT
Permian Basin Royalty Trust
$0.161.25%N/A32.65%N/A

Latest REDX, IXI, MEM, PBT, and MBX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/22/2025
Permian Basin Royalty Trust stock logo
PBT
Permian Basin Royalty Trust
$0.01301.3%6/30/20257/1/20257/15/2025
5/24/2025
Permian Basin Royalty Trust stock logo
PBT
Permian Basin Royalty Trust
$0.01882.01%5/30/20256/2/20256/13/2025
4/23/2025
Permian Basin Royalty Trust stock logo
PBT
Permian Basin Royalty Trust
$0.01962.35%4/30/20255/1/20255/14/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/AN/A
MEM
Matthews Emerging Markets Equity Active ETF
N/AN/AN/A
Permian Basin Royalty Trust stock logo
PBT
Permian Basin Royalty Trust
N/A
1.00
1.00
CompanyEmployeesShares OutstandingFree FloatOptionable
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
3633.42 millionN/AN/A
MEM
Matthews Emerging Markets Equity Active ETF
N/A1.22 millionN/ANot Optionable
Permian Basin Royalty Trust stock logo
PBT
Permian Basin Royalty Trust
N/A46.61 millionN/AOptionable

Recent News About These Companies

PBT Permian Basin Royalty Trust - Seeking Alpha
Permian Basin Trust sues Blackbeard over royalties
Permian Basin Royalty Trust cuts dividend by 4.1%
Permian Basin Royalty Trust declares $0.0196 dividend

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
MBX Biosciences stock logo

MBX Biosciences NYSE:MBX

$12.40 -0.88 (-6.63%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$12.00 -0.40 (-3.23%)
As of 04:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Matthews Emerging Markets Equity Active ETF NYSEARCA:MEM

$32.55 +0.03 (+0.09%)
As of 07/10/2025 04:10 PM Eastern

The Matthews Emerging Markets Equity Active ETF (MEM) is an exchange-traded fund that mostly invests in total market equity. The fund is actively managed to invest in emerging market companies with perceived sustainable growth potential. MEM was launched on Jul 13, 2022 and is managed by Matthews.

Permian Basin Royalty Trust stock logo

Permian Basin Royalty Trust NYSE:PBT

$12.76 0.00 (0.00%)
Closing price 07/10/2025 03:59 PM Eastern
Extended Trading
$12.80 +0.04 (+0.35%)
As of 04:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Permian Basin Royalty Trust, an express trust, holds royalty interests in various oil and gas properties in the United States. The company holds a 75% net overriding royalty interest in the Waddell Ranch properties, including Dune, Sand Hills (Judkins), Sand Hills (McKnight), Sand Hills (Tubb), University-Waddell (Devonian) and Waddell fields in Crane County, Texas. It also holds a 95% net overriding royalty in the Texas Royalty properties, which consist of various producing oil fields, such as Yates, Wasson, Sand Hills, East Texas, Kelly-Snyder, Panhandle Regular, N. Cowden, Todd, Keystone, Kermit, McElroy, Howard-Glasscock, Seminole, and others located in Texas. Its Texas Royalty properties comprise approximately 125 separate royalty interests containing approximately 51,000 net producing acres. The company was founded in 1980 and is based in Dallas, Texas.